A father’s desire to keep his daughter safe at school leads to an algorithm to predict blood glucose trends for those who use multiple daily injections.
An overview of all the potential threats to insulin from temperature variability, from the butter drawer in your fridge to the mail-order package baking on your front porch.
An interview with pediatric endocrinologist Dr. Mark Clements of Children’s Mercy Hospital in Kansas City. Dr. Clements sits on the IT subcommittee for the T1D Exchange Quality Improvement Collaborative.
The Libre 2 is now available in Europe, but no timetable has been given by Abbott officials for seeking FDA approval.
Forxiga (Farxiga in the United States) is an SGLT2 inhibitor that has been shown to lower HbA1c levels, but it comes with a somewhat elevated risk of diabetic ketoacidosis (DKA).
Forced exit from the closed-loop pump system’s basal delivery automode was the most common reason given, according Boston Children’s Hospital endocrinologist Dr. Gregory Goodwin.
T1D Exchange Glu’s editorial and communications manager shares how he found the silver lining of his type 1 diabetes diagnosis.
In a sharp-tongued argument, the political satirist argues that pharmaceutical companies and pharmacy benefit managers share the blame for runaway increases in drug pricing.
We take a moment to thank everyone who has taken part, and to discuss the future of our community.
How Diamyd Medical, a T1D Exchange Diabetes Innovation Challenge semifinalist, is doggedly pursuing immunotherapy to halt the destruction of insulin-producing beta cells.